RESUMO
BACKGROUND: Intestinal failure (IF) was first defined as "a reduction in the functioning gut mass below the minimal amount necessary for adequate digestion and absorption." In our environment, there are no statistical data for IF in adult patients' extended length of stay (LOS), nor the economic impact that it implies. OBJECTIVE: The objective of the study was to describe the association between the IF type and extended LOS. METHODS: Patients admitted to our IF Unit between March 2016 and March 2018 were enrolled. We conducted a 2-year retrospective cross-sectional study. RESULTS: From the total of 53 patients, 35% corresponded to type I IF, 58.5% to type II IF, and 7.5% to type III IF. The mean LOS, according to the type of functional IF was 51 days for type I, 77.48 days for type II, and 68.25 days for type III. The mean LOS for the three IF types was 67.79 days. CONCLUSION: Extended LOS occurs in an important proportion of patients with IF, resulting in increased morbidity and mortality, as well as in costs and associated side effects. Future research should focus on economic studies, to know the economic impact that this subject entails for our health systems.
ANTECEDENTES: En nuestro entorno no existen datos estadísticos sobre la falla intestinal en adultos, su estancia hospitalaria prolongada (EHP) ni el impacto económico que implica. OBJETIVO: Describir la asociación entre el tipo de falla intestinal y la estancia hospitalaria prolongada en pacientes de la unidad de falla intestinal del Hospital Central del Estado Chihuahua, México. MÉTODO: Se realizó un estudio transversal retrospectivo con un total de 53 participantes durante el periodo de marzo de 2016 a marzo de 2018. RESULTADOS: De los 53 pacientes, el 35% tuvieron falla intestinal tipo I, el 58.5% tipo II y el 7.5% tipo III. La media de estancia fue de 51 días para la falla intestinal tipo I, 77,48 días para la tipo II y 68,25 días para la tipo III. La media de estancia hospitalaria para los tres tipos de insuficiencia intestinal fue de 67,79 días. CONCLUSIONES: La estancia hospitalaria prolongada ocurre en una proporción importante de pacientes con falla intestinal, lo que resulta en un aumento de la morbilidad, la mortalidad y los costos. Investigaciones futuras deberían centrarse en la realización de estudios económicos para conocer el impacto que esta cuestión tiene para nuestros sistemas de salud.
Assuntos
Hospitalização/estatística & dados numéricos , Enteropatias/classificação , Escores de Disfunção Orgânica , Estudos Transversais , Custos Hospitalares/estatística & dados numéricos , Unidades Hospitalares/economia , Unidades Hospitalares/estatística & dados numéricos , Hospitalização/economia , Humanos , Enteropatias/epidemiologia , Enteropatias/cirurgia , Enteropatias/terapia , Tempo de Internação/economia , Tempo de Internação/estatística & dados numéricos , México/epidemiologia , Complicações Pós-Operatórias/economia , Complicações Pós-Operatórias/epidemiologia , Estudos RetrospectivosRESUMO
Solitary bone plasmacytoma (SPB) can progress to generalized myeloma if not treated early. The elderly population is increasing and delays in diagnosis of plasma cell malignancies are frequent among them. Hyperglobulinemia of multiple myeloma (MM) plays a role in hyperviscosity syndrome (HVS). A 65-year-old woman with hypertension and diabetes mellitus was admitted due to loss of appetite, muscle weakness, breathlessness and discrete expectoration, without fever. Chest X-ray showed an abnormal shadow projection on the right lung field, while computed tomography (CT) revealed an osteolytic mass at the sixth rib. There were more than 50% of plasma cells in the bone marrow samples and high IgA levels according to serum electrophoresis. Rib plasmacytoma and overt IgA-producing myeloma with HVS were diagnosed, but treatment was unsuccessful. Case studies may enhance the awareness about this ominous condition, which may develop unnoticed, particularly in elderly patients with renal insufficiency, and can pose difficulties with diagnosis in primary care settings.
Assuntos
Viscosidade Sanguínea , Neoplasias Ósseas/sangue , Neoplasias Ósseas/complicações , Mieloma Múltiplo/sangue , Mieloma Múltiplo/complicações , Plasmocitoma/sangue , Plasmocitoma/complicações , Costelas , Idoso , Feminino , Humanos , Imunoglobulina A , Mieloma Múltiplo/imunologia , SíndromeRESUMO
Relata-se o caso de uma mulher jovem assintomática com carcinoma de mama disseminado, que foi diagnosticado no puerpério. Foram detectadas metástases nos ossos, nos pulmões, no fígado e no sistema nervoso central. A paciente foi tratada com quimioterapia intravenosa (paclitaxel e bevacizumabe), além de radioterapia para a lesão no putâmen. Câncer de mama associado à gravidez constitui uma condição de mau prognóstico devido à demora no diagnóstico, e sua incidência tem aumentado nas últimas décadas. Embora considerada condição incomum e os relatosde caso sejam relativamente escassos, sua real frequência pode estar subestimada. A identificação dessa neoplasia durante a gravidez ou a lactação pode constituir um desafio devido à possibilidade de confundi-la com alterações fisiológicas das mamas. Recentes controvérsias sobre o uso de bevacizumabe no câncer de mama são comentadas
The case of an asymptomatic young woman with a widespread breast cancer, which was diagnosed in the puerperium is reported. Metastases were detected in the bones, lungs(?), liver and central nervous system. The patient was treated with intravenous chemotherapy (paclitaxel and bevacizumab), and radiotherapy for the lesion on putamen. Pregnancy-associated breast cancer constitutes a condition of poor prognosis due to diagnosis delay and its incidence has increased in the last decades. Although considered an uncommon condition, and case reports arerelatively scarce its real frequency may be underestimated. The identification of this neoplasm during pregnancy or lactation may be challenging, due to the possibility of misdiagnosis with physiologic changes of the breasts. Recent controversies about the utilization of bevacizumab in breast cancer are commented.
RESUMO
The incidence and mortality of malignant melanoma is increasing. Its early diagnosis can contribute to a favorable prognosis. We report a 74-year-old black man with a dark brown mole in the right plantar area, that grew slowly in the last decade. A biopsy of the lesion revealed a nodular malignant melanoma. A wide excision of the tumor was performed 18 months ago, followed by chemotherapy for nine months. At admission, the patient was debilitated, and presented with numerous nodules in the lower limb and suprapubic area. Imaging studies disclosed chest and abdominal nodules. The patient died 13 days after admission.
Melanoma maligno constituye una importante preocupación debido al incremento de la incidencia y mortalidad. El diagnóstico precoz de esta malignidad puede contribuir para prognósticos favorables. Se describe el diagnóstico tardío de melanoma nodular del pie en un varón afro-brasileño con 74 años de edad. El propósito es aumentar el índice de sospecha acerca de esta infrecuente localización del tumor de la piel, y estimular a los médicos de cuidado primario para realizar examen minucioso del cuerpo entero, contribuyendo a la detección temprana de los cánceres de piel.
Assuntos
Idoso , Humanos , Masculino , Neoplasias Abdominais/secundário , Doenças do Pé/patologia , Neoplasias Pulmonares/secundário , Melanoma/secundário , Neoplasias Cutâneas/patologia , Diagnóstico Tardio , Evolução FatalRESUMO
The incidence and mortality of malignant melanoma is increasing. Its early diagnosis can contribute to a favorable prognosis. We report a 74-year-old black man with a dark brown mole in the right plantar area, that grew slowly in the last decade. A biopsy of the lesion revealed a nodular malignant melanoma. A wide excision of the tumor was performed 18 months ago, followed by chemotherapy for nine months. At admission, the patient was debilitated, and presented with numerous nodules in the lower limb and suprapubic area. Imaging studies disclosed chest and abdominal nodules. The patient died 13 days after admission.